Her current research interests include the pharmacokinetics and imaging of anti-tuberculosis drugs in pulmonary lesions, the molecular mechanisms driving intracellular accumulation of TB drugs in Mycobacetrium and in macrophages, and the optimization of predictive animal models and in vitro assays to study these questions. With funding from the Gates Foundation and the NIH, research activities in the Dartois lab focus on the pharmacokinetics and pharmacodynamics of anti-tuberculosis agents in pulmonary TB lesions, in the rabbit model and through clinical research studies. Specifically, lesion-specific analysis of drug exposure and bacetrial killing help identify and characetrize lung granuloma compartments in which organisms are not eliminated. In the context of failing TB control programs and global emergence of drug resistance, this information can guide a more rational approach to designing treatment regimens that ensure optimal drug exposure at the site of infection. Recent reports suggesting that many of the 1st line drugs may be sub-optimally dosed highlight the importance of these studies.